1. Home
  2. THRD vs TRDA Comparison

THRD vs TRDA Comparison

Compare THRD & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • TRDA
  • Stock Information
  • Founded
  • THRD 2019
  • TRDA 2016
  • Country
  • THRD United States
  • TRDA United States
  • Employees
  • THRD N/A
  • TRDA N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • TRDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • THRD Health Care
  • TRDA Health Care
  • Exchange
  • THRD Nasdaq
  • TRDA Nasdaq
  • Market Cap
  • THRD 513.2M
  • TRDA 609.7M
  • IPO Year
  • THRD 2022
  • TRDA 2021
  • Fundamental
  • Price
  • THRD $10.84
  • TRDA $17.59
  • Analyst Decision
  • THRD Strong Buy
  • TRDA Strong Buy
  • Analyst Count
  • THRD 3
  • TRDA 4
  • Target Price
  • THRD $20.33
  • TRDA $24.75
  • AVG Volume (30 Days)
  • THRD 259.3K
  • TRDA 128.9K
  • Earning Date
  • THRD 11-07-2024
  • TRDA 11-05-2024
  • Dividend Yield
  • THRD N/A
  • TRDA N/A
  • EPS Growth
  • THRD N/A
  • TRDA N/A
  • EPS
  • THRD N/A
  • TRDA 1.55
  • Revenue
  • THRD N/A
  • TRDA $215,232,000.00
  • Revenue This Year
  • THRD N/A
  • TRDA $47.45
  • Revenue Next Year
  • THRD N/A
  • TRDA N/A
  • P/E Ratio
  • THRD N/A
  • TRDA $11.34
  • Revenue Growth
  • THRD N/A
  • TRDA 146.92
  • 52 Week Low
  • THRD $8.08
  • TRDA $11.35
  • 52 Week High
  • THRD $16.94
  • TRDA $21.79
  • Technical
  • Relative Strength Index (RSI)
  • THRD 40.49
  • TRDA 41.90
  • Support Level
  • THRD $10.53
  • TRDA $17.26
  • Resistance Level
  • THRD $11.84
  • TRDA $18.96
  • Average True Range (ATR)
  • THRD 0.86
  • TRDA 1.03
  • MACD
  • THRD -0.07
  • TRDA -0.38
  • Stochastic Oscillator
  • THRD 17.60
  • TRDA 14.81

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Share on Social Networks: